Previous 10 | Next 10 |
2023-12-28 15:06:23 ET More on AbbVie, Amgen, etc. The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Bristol Myers Squibb: Too Many Headwinds To Ignore, Despit...
2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...
2023-12-27 10:29:37 ET More on Cytokinetics Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade) Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript ...
2023-12-27 10:00:08 ET Summary Cytokinetics' share price surged after announcing positive results from the phase 3 SEQUOIA-HCM trial of aficamten. Aficamten showed better efficacy, safety, and convenience compared to Camzyos, positioning it as a potential best-in-class drug. T...
2023-12-22 18:18:15 ET Summary Today, we revisit Bicycle Therapeutics plc, a UK-based clinical stage biotech company focused on developing medicines for underserved diseases. The company has inked two significant collaboration deals with large drug makers in 2023 and continues to ...
2023-12-21 10:02:35 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript Cytokinetics Q3 2023 Earnings Preview Cytokinetics surges amid report of takeover interest Seeking Alpha’s Quant Rating on Cytokinetics ...
2023-12-19 13:13:17 ET Summary TG Therapeutics, Inc. stock has gone up a lot due to a Q3 revenue beat. However, look closely at the Q3 numbers, and you can see Briumvi wasn't responsible for the revenue beat. Briumvi hasn't done as well as it should have. My TG The...
2023-12-18 23:16:26 ET Summary Lantheus stock dropped 26% post-SPLASH study, highlighting risks in mCRPC drug development and its strategic alliance with POINT Biopharma. SPLASH trial met primary goals but showed underwhelming overall survival data, affecting investor confidence a...
2023-12-14 12:30:25 ET The Biden administration on Thursday named 48 Medicare Part B drugs that could be subject to inflation penalties for Q1 2024, including products from the likes of AbbVie ( NYSE: ABBV ), Amgen ( NASDAQ: AMGN ), and Pfizer ( NYSE: PFE ). Drug...
2023-12-14 10:33:42 ET More on Amgen Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks Amgen: Buy In Stable Fundamental And Technical Price Growth Amgen gets FDA pr...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...